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Central Pain Mechanisms in the Rheumatic Diseases
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Introduction
Pain is a prominent component of many rheu-
matologic conditions and is the result of a complex
physiologic interaction of central and peripheral ner-
vous system signaling that results in a highly individual-
ized symptom complex. Pain is frequently categorized
as acute or chronic (generally 3 months’ duration).
Chronic pain is not simply acute pain that has lasted
longer; it is more likely to be influenced by input from
the central nervous system, whereas acute pain is often
attributable primarily to inflammation and/or damage in
peripheral structures (i.e., nociceptive input).
The prominent role of central factors in chronic
pain is highlighted by the fact that there is currently no
chronic pain condition in which the degree of tissue
inflammation or damage alone (e.g., as measured by
radiographs, magnetic resonance imaging [MRI], or
endoscopy) accurately predicts the presence or the se-
verity of pain. Central factors alter pain processing by
setting the “gain,” such that when peripheral input is
present, it is processed against a background of central
factors that can enhance or diminish the experience of
pain. There are very large interindividual differences in
these central nervous system factors that influence pain
perception, such that some individuals with significant
peripheral nociceptive input (e.g., from joint damage or
inflammation) will feel little or no pain, whereas others
are very pain sensitive, and they can experience pain
with minimal or no identifiable abnormal peripheral
nociceptive input. This emerging knowledge has impor-
tant implications for pain management in individuals
with chronic rheumatologic disorders.
Pain in rheumatologic disorders
Although most patients seen by rheumatologists
have pain as their presenting complaint, most rheuma-
tologists have little formal training about contemporary
theories regarding pain processing or pain manage-
ment. Because of this, educating rheumatologists and
others involved in the care of individuals with musculo-
skeletal pain has become a priority. The American
College of Rheumatology Pain Management Task Force
highlighted this in an initiative to increase awareness and
call for organized research and education concerning
chronic pain (1). Chronic pain may encompass pathol-
ogy of the joint, skin, muscles, or peripheral nerves
associated with rheumatologic diseases. A better under-
standing of chronic pain mechanisms will help us under-
stand individual differences in pain among patients
with rheumatic diseases, and this will in turn allow for a
more targeted approach to treatment (i.e., personalized
analgesia) (2).
The concept of centralized pain
The term “central pain” was originally used to
describe the condition in individuals who developed pain
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following a stroke or spinal cord lesion. In this case,
“central” refers to the fact that the lesion leading to pain
occurred within the central nervous system (CNS). More
recently, however, the term has been expanded to de-
scribe any CNS dysfunction or pathologic condition that
may be contributing to the development or maintenance
of chronic pain (3), which includes, but is not limited to,
important contributions from psychosocial aspects of
pain perception. Another term that has often been used
to describe this same phenomenon is “central sensitiza-
tion.” The term central sensitization was originally used
to describe a state in which the spinal cord amplifies
afferent signals out of proportion to peripheral tissue
changes. This term has the same problem as the term
“central pain” because it originally referred to a specific
mechanism, representing only one potential cause of
augmented CNS pain processing (4).
For clarity, we will use terms such as central
augmentation or amplification to refer more broadly to
central mechanisms that enhance the perception or
modulation of pain differentially between individuals.
We will use the term centralization of pain to refer to a
common process that seems to occur to a vulnerable
subset of individuals with any chronic pain state, wherein
pain primarily due to peripheral nociceptive input is
subsequently amplified by central factors, such that both
peripheral and central factors are then contributing to
the individual’s perception of pain. This latter phenom-
enon is particularly important for rheumatologists to
identify because these are individuals in whom our
commonly used peripherally directed therapies (e.g.,
disease-modifying antirheumatic drugs [DMARDs], sur-
gery) are unlikely to be effective as sole therapies.
Centralized pain was originally thought to be
confined to individuals with rare structural causes of
pain or those with idiopathic or functional pain syn-
dromes, such as fibromyalgia (FM), headache, irritable
bowel syndrome (IBS), temporomandibular joint dis-
order (TMJD), and interstitial cystitis (5). These pain
syndromes have been shown to be very familial/genetic
(e.g., the risk of developing FM is 8-fold higher in first-
degree relatives of patients with FM) and to coaggregate
in families (3,6). Twin studies also support a strong
familial basis for pain as well as for this cluster of
coaggregating symptoms (7,8). Even if these individuals
are initially thought to have new onset of a regional pain
syndrome, closer questioning often reveals that they
have had many different regions of chronic pain over
the course of their lifetime or even at present (9). Thus,
taking both a personal history of chronic pain and a
family history of chronic pain is a clinical pearl that can
be helpful in identifying individuals who have (or are at
risk of developing) prominent centralization of pain.
Another marker of “central” pain is the occur-
rence of multifocal pain in conjunction with other cen-
trally mediated symptoms, such as fatigue, insomnia,
memory difficulties, and mood disturbances (10,11).
One of the simplest ways to identify individuals whose
pain has become centralized is to suspect that this has
occurred when those with chronic pain have several of
these other symptoms as comorbidities (3,12). Regard-
ing the clustering of co-occurring somatic symptoms, as
well as the higher than expected rates of mood disorders,
the leading pathophysiologic theory concerning these
central pain states is that centrally acting neurotrans-
mitters that are known to be abnormal and likely to play
a role in causing the pain in these conditions (e.g., low
norepinephrine, GABA, or serotonin levels and high
glutamate or substance P levels) also play prominent
roles in controlling sleep, mood, alertness, etc. (3,13).
This hypothesis is best supported by the fact that when
centrally acting analgesics, such as selective serotonin
and norepinephrine reuptake inhibitors (SSNRIs), ga-
bapentinoids, tricyclics, or -hydroxybutyrate, are effec-
tive in a given patient with chronic pain, these drugs
typically lead to improvements in one or more of these
other symptom domains besides pain (14–16).
In addition to the study of symptom domains in
central pain states, significant advances have been made
in our understanding of the pathogenesis of chronic
pain. The hallmark biologic finding common to these
“centrally driven” conditions is that most individuals
have a diffuse CNS hyperalgesic state that is identifiable
by quantitative sensory testing and can be corroborated
by functional neuroimaging (6,17–19). Data from quan-
titative sensory testing and functional neuroimaging
studies suggest wide individual variations in pain and
sensory sensitivity that adhere to a bell-shaped distri-
bution across a wide variety of chronic pain states, with
a subset of individuals displaying hyperalgesia or aug-
mented CNS activity across pain states (3,6,18,20,21).
Some of the discrete conditions originally identified
as being central pain states because of the presence of
diffuse hyperalgesia and a lack of obvious, ongoing
peripheral nociceptive input include FM, IBS, TMJD,
tension headache, interstitial cystitis, and vulvodynia
(22–29).
The baseline presence of hyperalgesia and/or the
absence of descending analgesic activity has not only
been shown to be present in individuals with these
centralized pain states, but has also been shown to be an
important risk factor for a number of adverse pain
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outcomes, including predicting the subsequent intensity
of an acute painful experience, the analgesic require-
ments following surgery, and the subsequent develop-
ment of chronic pain (30–32). This latter phenomenon
was first demonstrated in a study by Diatchenko and
colleagues (33), who performed a longitudinal study of
202 young, pain-free women whose cases they followed
for 2 years, with the outcome of interest being the
development of new-onset TMJD. An individual’s pain
threshold at baseline (i.e., while asymptomatic) was a
strong predictor of the development of TMJD, since any
individual on the “hyperalgesic side” of a bell-shaped
curve of pain sensitivity at baseline was found to be
nearly 3 times as likely to develop TMJD as an individual
in the bottom half of pain sensitivity.
This study was among the first to highlight the
strong role that certain genes play in turning up the
“gain” on pain processing (6,33,34) and in identifying
one cause of a “chronic pain–prone phenotype.” Hyper-
sensitivity of nonpainful stimuli in sensitized pain pa-
tients is a hallmark of chronic pain. The early genetic
data were consistent with those of studies performed
by Zubieta et al (35), who several years earlier, had
shown that catechol-O-methyltransferase (COMT) poly-
morphisms predicted pain thresholds (as measured both
by quantitative sensory testing and by functional neuro-
imaging) in healthy individuals. The same COMT gene
risk allele has subsequently been shown to be more
common in conditions such as FM and to exert a rela-
tively large effect in experimental pain sensitivity in
humans, as well as responsiveness to and side effects
from commonly used analgesics (35–39). Just as we
know of tremendous variability in pain sensitivity be-
tween strains of rodents, there similarly is great variabil-
ity in pain sensitivity in humans (40). At least 5 sets of
genes are associated with an individual’s pain sensitivity
and increase their likelihood of developing one or more
chronic pain states. These include COMT (an estrogen-
sensitive enzyme that may play a more prominent role
in females), GTP cyclohydroxylase, types 2 and 3 adren-
ergic receptors, a P2X7 receptor pore, and sodium or
potassium channel genes (35,41–46). While some genes
have been consistently shown to confer a higher risk of
pain sensitivity or the development of chronic pain,
this is a rapidly evolving area, and not all studies have
demonstrated the same associations (41,47–49).
Kato and colleagues (8), using a large Swedish
twin registry, performed a series of studies that first
showed the comorbidities with chronic widespread pain,
and then later, they examined a number of these central
or “functional” pain syndromes and the relationship of
these symptoms to those of depression and anxiety.
Those studies clearly demonstrated that functional so-
matic syndromes, such as FM, CFS, IBS, and headache,
have latent traits (e.g., multifocal pain, fatigue, memory
and sleep difficulties) that are different from, but over-
lap somewhat with, psychiatric conditions such as anxi-
ety and depression. These findings are also consistent
with the results of functional neuroimaging studies. For
example, individuals with FM alone primarily have in-
creased activity in the regions of the brain that code for
the sensory intensity of stimuli (e.g., the primary and
secondary somatosensory cortices, posterior insula, thal-
amus), whereas the FM patients with comorbid depres-
sion also have increased activation in brain regions
coding for the affective processing of pain, such as the
amygdala and anterior insula (50). The notion that there
are 2 overlapping sets of traits, one being pain and
sensory amplification and the other being mood and
affect, is also supported by genetic studies of idiopathic
pain syndromes (6). Twin studies have also been useful
in helping tease out potential underlying mechanisms
versus “epiphenomena.” Those investigators suggested
that there is evidence of a problem with biologic sensory
amplification in the affected twins (51).
As with most illnesses that may have a familial or
genetic underpinning, environmental factors may play a
prominent role in triggering the development of FM and
other centralized pain states. Environmental “stressors”
temporally associated with the development of wide-
spread pain include early life trauma, physical trauma
(especially involving the trunk), and certain infections,
such as hepatitis C virus, Epstein-Barr virus, parvovirus,
Lyme disease, and emotional stress. The disorder is also
associated with other regional pain conditions or auto-
immune disorders (52–54). Of note, each of these “stres-
sors” only triggers the development of fibromyalgia and/
or chronic fatigue syndrome in 5–10% of individuals
who are exposed; the overwhelming majority of indi-
viduals who experience these same infections or other
stressful events regain their baseline state of health.
In fact, emerging evidence from a number of
different areas in the study of pain suggests that the
same characteristics that are often attributable to FM
patients in fact more broadly represents a “pain-prone
phenotype.” As shown in Figure 1, female sex, early life
trauma, a personal or family history of chronic pain, a
personal history of other centrally mediated symptoms
(insomnia, fatigue, memory problems, mood distur-
bances), and cognitions such as catastrophizing have all
been shown to be present in subsets of individuals with
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any chronic pain state and to predict which individuals
are more likely to transition from acute pain to chronic
pain.
Functional neuroimaging studies, especially those
using functional MRI, also corroborate the findings of
quantitative sensory testing for diffuse hyperalgesia/pain
augmentation by demonstrating that individuals with
central pain states have increased neuronal activity in
pain-processing regions of the brain when they are
exposed to stimuli that healthy individuals find in-
nocuous (29,55–57). Several meta-analyses of func-
tional MRI studies have summarized the brain regions
that show activation when experimental pain is applied
to human subjects, and these generally are consistent
with the findings of single-photon–emission computed
tomography (SPECT) and positron emission tomography
(PET) studies noted above. The main components of
this pain-processing matrix are the primary and second-
ary somatosensory cortex, the insular cortex, the ante-
rior and midcingulate cortex, the posterior cingulate
gyrus, and the thalamus; that is, the pain system involves
somatosensory, limbic, and associative brain structures
(58,59). Within a single brain region, such as the insula,
the posterior insula is more involved in sensory process-
ing and the anterior more involved in affective process-
ing, and even the left-to-right balance of insular activity
may be associated with the emotional valence of pain (60).
Many potential mechanisms can cause aug-
mented central pain processing. The two receiving the
most attention and study have been increased wind-up
and diminished descending analgesia or conditioned
pain modulation. Wind-up is a perceived increase in
pain intensity when a stimulus is repeated above a
certain rate and is mediated by C fibers. Descending
analgesia is a function of descending neural pathways
that form a pain-modulating circuit. The integrity and
magnitude of this conditioned pain modulation (CPM),
or diffuse noxious inhibitory control (DNIC), system
can be tested by using 2 separate painful stimuli and
observing the fact that experiencing the first painful
stimulus can reduce the perceived intensity of the sec-
ond one. While both wind-up and CPM can be tested
experimentally, data thus far suggest that the study of
descending endogenous analgesic pathways holds the
most promise for successfully identifying those with
central predominance to their pain. For example, atten-
uated descending analgesic activity (experimentally ob-
served as reduced DNIC or CPM) is seen in 10–20% of
controls, but this deficit is demonstrated in 60–80% of
individuals with conditions such as FM or IBS (61–66).
Neither diffuse hyperalgesia nor reduced DNIC/CPM
(deficiencies in descending analgesic activity) is gener-
ally seen in individuals with psychiatric disorders such as
depression (50,67).
An analogy of an increased “volume control” or
“gain” setting on pain and sensory processing is sup-
ported by studies from a variety of sources. Elevated
levels of neurotransmitters that tend to be pronocicep-
Figure 1. Development of expanded pain regions in patients prone to experiencing central pain.
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tive (those shown on the left side of Figure 2) or reduced
levels of neurotransmitters that inhibit pain trans-
mission (those shown on the right side of Figure 2) have
a tendency to increase the volume control, and drugs
that block the neurotransmitters shown on the left
Figure 2 or augment the activity of those shown on the
right will typically be found to be effective treatments,
at least for a subset of individuals with this spectrum of
illness. As noted, there is evidence of increases in the
CSF levels of substance P, glutamate, nerve growth
factor, and brain-derived neurotrophic factor, and low
levels of the metabolites of serotonin, norepinephrine,
dopamine, and GABA can lead to an “increase in the
volume control” and augmented pain and sensory proc-
essing (68–72). The only neurotransmitter system that
has thus far been studied and not found to be inconsis-
tent in a direction that would cause augmented pain
transmission is the endogenous opioid system. This
may be one reason why opioid drugs do not work well in
the treatment of FM and related centralized pain con-
ditions (73,74).
Potential role of peripheral factors in central pain
states
Immunologic cascades play a role in the mainte-
nance of central sensitivity and chronic pain, which is
enhanced through the release of proinflammatory cyto-
kines by CNS glial cells; thus, the traditional paradigm
regarding inflammatory versus noninflammatory pain
may gradually become less dichotomous. As may be
expected in any complex biologic system, a delicate
apparatus of checks and balances is at work in the spinal
transmission of pain. Furthermore, studies suggest that
maintenance of central augmentation requires persistent
noxious peripheral input, even in syndromes such as IBS
and FM, which are characterized by the absence of well-
defined, localized, pain-causing lesions (75). In fact, a
recent study of 68 fibromyalgia patients with myofascial
pain syndromes and 56 fibromyalgia patients with re-
gional joint pain showed that peripheral trigger point
injections and hydroelectrophoresis ameliorate fibromy-
algia pain and increase pain thresholds at sites distant
Figure 2. Influences of the central nervous system (CNS) on pain and sensory processing. Recent studies have demonstrated that an individual’s
“set point” or “volume control setting” for pain is determined by a variety of factors, including the levels of neurotransmitters shown on the left,
which facilitate pain transmission (turn up the gain or the volume control), or the neurotransmitters shown on the right, which reduce pain
transmission. Thus, high levels of the neurotransmitters on the left or low levels of those on the right would be capable of causing the diffuse
hyperalgesia (increased volume control) that is seen in a variety of chronic pain states. EAA  excitatory amino acid; 5-HT2A  5-hydroxytryptamine
H2A; GABA  -aminobutyric acid.
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from the therapeutic interventions, providing further
evidence that painful peripheral stimuli contribute to the
perpetuation of central augmentation interventions (76).
The role of centralized pain in classic rheumatic
diseases
Rheumatologists have known for some time that
as many as 15–30% of individuals with classic auto-
immune or rheumatic disorders also have comorbid FM,
which was once referred to as “secondary FM” (77).
These rates are much higher than the prevalence of FM
in the general population (2%), suggesting that pain
and/or stress accompanying chronic rheumatic diseases
is one way that conditions such as FM can be triggered.
Triggering of a centralized pain state can also be seen
with certain types of trauma, such as motor vehicle
collisions, by infections such as Borrelia burgdorferi in
Lyme disease or Epstein-Barr virus, and following sur-
gery or deployment in war (78–81). This suggests that
many biologic stressors, especially those accompanied
by acute pain, are capable of triggering centralization or
chronic pain.
Wolfe coined the term “fibromyalgianess” to con-
note the fact that regardless of whether individuals with
rheumatic disorders have FM as a “categorical” diagno-
sis (i.e., yes or no) or whether this construct is measured
as a continuous variable, the more general construct of
FM is highly associated with levels of pain and disability
across all rheumatic disorders (82,83). Fibromyalgia
(dichotomous diagnosis) and fibromyalgianess (mea-
sured as a continuous variable) directly affect traditional
measures of disease activity and severity, and have
implications for clinical practice (84). Partial fulfillment
of the 2010 revised criteria for FM may prove useful in
discerning patients who are at risk of developing chronic
pain but do not meet diagnostic criteria for FM. The
degree of fibromyalgianess also influences objective and
subjective responses to therapy with biologic and non-
biologic DMARDs in RA and predicts worse pain and
functional status following total joint arthroplasty and
back surgery.
Osteoarthritis (OA). Historically, the “disease”
of OA has been viewed primarily as damage to the
cartilage and bone. As such, the magnitude of damage or
inflammation of these structures should predict symp-
toms. Population-based studies suggest otherwise; 30–
50% of individuals with moderate-to-severe radio-
graphic changes of OA are asymptomatic, and 10% of
individuals with moderate-to-severe knee pain have nor-
mal findings on radiography (85,86). Psychological fac-
tors do account for some of this variance in pain and
other symptoms, but only to a small degree (87,88). The
fact that central factors may play a pivotal role in OA
helps to explain the fact that comorbid somatic symp-
toms known to be associated with central pain condi-
tions (e.g., fatigue, sleep problems) are very common in
OA and are not explained by a purely “peripheral”
model of this disorder (89–91).
Moreover, for some time, there have been small
studies suggesting that OA patients display diffuse hy-
peralgesia to mechanical or heat stimuli (92). Kosek and
Ordeberg (93) demonstrated that individuals with OA of
the hip had reduced descending analgesic activity, which
partially normalized following hip arthroplasty, suggest-
ing that the central factors were being at least partly
driven by peripheral nociceptive input. Since then, larger
and more comprehensive studies have been performed,
showing that groups of individuals with OA have lower
overall thresholds for pain than do controls and have
less efficient descending analgesic activity (92,94). Most
recently, Gwilym and colleagues (20,95) used both ex-
perimental pain testing and more sophisticated func-
tional neuroimaging procedures to show evidence of
augmented CNS processing of pain in 20 OA patients
and then showed in a separate study that atrophy of the
thalamus was seen at baseline in OA and improved
following arthroplasty. Finally, recent randomized con-
trolled trials have demonstrated that compounds that
alter pain neurotransmitters centrally, such as serotonin
and norepinephrine (e.g., duloxetine, tricyclics), are
efficacious in OA (96,97).
This does not at all mean that peripheral factors
are unimportant in OA. A recent study by Neogi and
colleagues (98) elegantly demonstrated that in individu-
als with asymmetric knee OA, the pain levels in each
knee strongly related to joint space narrowing in the
affected knee. The aggregate data instead suggest that in
some individuals, central factors are superimposed upon
the more traditional peripheral factors (targeted by
nonsteroidal antiinflammatory drugs [NSAIDs], for ex-
ample) leading to the need for a broader and more
flexible approach to diagnosis and treatment.
Systemic lupus erythematosus (SLE). For some
time, it has been suspected that FM is a common
comorbid condition in SLE and confounds both the
diagnosis and treatment of SLE (99–101). For example,
just as with other rheumatic disorders, neither the
degree of inflammation nor the degree of damage is
highly associated with pain, fatigue, function, or other
symptoms of SLE (102–104). Instead, the presence or
absence of comorbid FM (which occurs in 20% of
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patients with SLE as well as other autoimmune disor-
ders) is often the largest predictor of pain, fatigue, and
function in patients with SLE (77,105). FM and pheno-
typical features of centralized pain are more related to
quality of life measures than to disease activity per se
(106). As individual domains, the presence of FM in
SLE is most closely associated with fatigue, sleep distur-
bances, psychiatric disturbances, and work disability
(107–109).
Additional studies are needed to explore the role
that the “centralization-prone phenotype” plays in pre-
dicting which SLE patients will eventually develop co-
morbid FM or centralization of their pain. There has
been very little quantitative sensory testing performed to
date in SLE. Hyperalgesia, as crudely measured by a
tender point count, is an uncommon finding in groups of
SLE patients and is related to measures of health status
and disease activity (110). Only a single published study
has used functional neuroimaging in SLE. Areas of CNS
hypoperfusion noted in patients with SLE overlapped
with those seen in patients with FM alone, as well as in
patients with SLE and FM in combination (111).
Rheumatoid arthritis (RA). In contrast to FM
and OA, RA is characterized by systemic inflammation.
Although inflammation contributes to pain in RA, it
may not be the only factor. For many patients, pain does
not improve upon treatment with antiinflammatory
DMARDs (82). Although few studies have specifically
examined the role of central pain–processing mecha-
nisms in RA, studies using dolorimetry to assess pain
thresholds suggest that these other pathways may in-
clude deficits in central pain processing. Early, small
studies suggested that groups of RA patients displayed
deficits in central pain processing, including impaired
descending analgesic activity (112,113). Wolfe et al (82)
showed that fibromyalgia is very prevalent in RA pa-
tients, and there is increased morbidity in patients who
have both RA and FM as compared to those who have
FM alone (114,115). It is important to remember that
centralization of pain may also have an impact on tra-
ditional measures of disease activity, such as the Disease
Activity Score in 28 joints. Lee and colleagues (116)
recently showed that in RA, the relationships between
inflammation, psychosocial factors, and peripheral and
central pain processing are intricately entwined. In their
study of 59 female patients with RA, they demonstrated
that C-reactive protein levels were inversely associated
with pain thresholds at joint, but not nonjoint, sites,
consistent with peripheral sensitization (116). In that
study, sleep disturbances were associated with pain
thresholds at both joint and nonjoint sites, indicating
that central mechanisms (i.e., central sensitization) likely
underlie the link between overall pain sensitivity and
sleep problems.
Future directions
Current and future studies in the rheumatic
diseases can be leveraged to take advantage of both
“primary” and “secondary” manifestations of FM and
centralized pain, both to learn more about FM and to
learn more about the pathogenesis and underpinnings
Figure 3. Characteristics of patients with rheumatologic diseases that may have contributions from central pain mechanisms.
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of chronic pain more generally. Subsets of individuals
in the population are more susceptible to developing
chronic pain and somatic symptoms following exposure
to sustained peripheral nociception and stress, and
the clinical and biologic features of these susceptible
individuals are reminiscent of those in patients with
subclinical FM, which has been characterized as a
“centralization-prone phenotype,” as outlined in Figure
3. When these individuals are exposed to the ongoing
pain and stress associated with a chronic rheumatic
disease, full-blown FM may be triggered in susceptible
individuals. Patients with OA, RA, or SLE whose pain
has already become “centralized” may show higher
levels of pain intensity and disease activity for the same
degree of inflammation or structural damage and may
be less responsive to classic, peripherally directed phar-
macologic (DMARDs) and nonpharmacologic (surgery)
therapies (19,117).
There is significant support for this idea, espe-
cially given recent evidence of prominent CNS contri-
butions to pain in conditions such as OA, RA, and low
back pain (20,29,44,82,97,118). Across the rheumatic
disorders, individuals with higher degrees of fibromyal-
gianess may preferentially respond to “centrally acting”
drugs (e.g. tricyclics, SSNRIs, gabapentinoids), whereas
those without evidence of centralization of their pain
will preferentially respond to drug classes historically
believed to work better on peripheral/nociceptive pain
(e.g., NSAIDs, opioids, DMARDs, surgery). Support
for these hypotheses would tremendously advance our
ability to offer personalized analgesia in routine clinical
practice.
The overall direction of chronic pain research is a
paradigm shift in the diagnosis and treatment of pain in
individuals with rheumatic disorders. Instead of consid-
ering pain and other symptoms associated with OA, RA,
and SLE to be primarily due to peripheral damage or
inflammation (i.e., nociception), the appropriate “pheno-
typing” (recognition of patients with traits and states
associated with the risk of developing chronic pain) of
patients with chronic pain can identify subsets of indi-
viduals with these disorders that have prominent CNS
contributions to their symptoms. Individuals with these
diseases will likely respond differentially to DMARDs
and nondrug therapies (such as surgical procedures per-
formed for pain). Since arthroplasty and other surgical
procedures performed to relieve chronic pain are very
expensive procedures and since it is acknowledged that
20–40% of individuals receiving such procedures con-
tinue to have significant knee pain at 1–2 years (119), a
tremendous opportunity exists for developing para-
digms by which to identify good (or poor) candidates for
these or other “analgesic surgeries,” rather than subject-
ing individuals to a procedure from which they would be
unlikely to derive any benefit. The same holds true for
many other procedures performed to treat pain, as well
as for the use of biologic immunosuppressive agents in
patients with persistent pain but equivocal evidence of
ongoing inflammation.
While there is knowledge to be gained from prior
studies in other centrally mediated syndromes, rheuma-
tologists should lead the way in developing and field-
testing new phenotyping or identification measures for
patients with rheumatologic diseases that will allow us to
infer which underlying mechanisms are causing an indi-
vidual’s pain, so that treatment(s) can be appropriately
directed. The pain field has moved well past the point
where we can consider all individuals with RA, SLE,
OA—or any chronic pain state, for that matter—to have
the same underlying mechanism of pain and other
somatic symptoms they experience. All of these symp-
toms are experienced in the brain. So, as a field, we need
to better understand the brain in order to better treat
our patients’ pain.
Identifying subsets of OA, SLE, and RA patients
with prominent CNS factors might also help explain a
longstanding conundrum in our fundamental under-
standing of these disorders. Disease models in OA, RA,
and SLE are incomplete because peripherally based
models do not explain a tremendous amount of variance
in pain, fatigue, sleep, memory problems, and functional
disability that is not accounted for by peripheral factors
alone. For example, although the pathologic focus in
OA is the joint and surrounding structures, multifocal
pain in areas not affected by OA is common in patients
with knee OA (120). Similarly, other somatic symptoms
not explainable by a purely peripheral problem are often
seen. For example, studies show fatigue to be a promi-
nent problem in individuals with knee OA, and in many
individuals, it is a more functionally limiting symptom
than the pain (121). The current peripherally based
theories regarding the pathogenesis of OA, SLE, and
RA simply do not explain why these other somatic
symptoms are so common and are often refractory to
standard, peripherally based therapies.
Conclusions
Chronic pain is an important component of
many rheumatic diseases. One current limitation is the
ability to identify patients in routine clinical settings who
have greater contributions from centrally mediated
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mechanisms. Practical evidence-based strategies need to
be developed that will more readily identify these pa-
tients at the point of care as well as in the context of
randomized clinical trials that include pain as an out-
come measure. Centrally targeted therapies have the
potential to change the treatment of chronic pain in
many diseases. Several classes of centrally acting agents
(e.g., tricyclics, SSNRIs, gabapentinoids) may prove to
be more effective in individuals with rheumatic disorders
who have a central pain overlay than classes of drugs
that are typically more effective for peripherally based
nociceptive pain states (e.g., NSAIDs), but additional
studies are needed to prove this. Newly developed pain
cohort studies should identify these subsets of RA, SLE,
and OA patients who are preferentially predisposed to
respond to these centrally, in addition to peripherally
acting treatments, including nonpharmacologic therapy.
There are few published results examining the role of
combination therapy in chronic pain, but it is likely that
such regimens will improve outcomes to the extent that
they are influenced by multiple distinct mechanisms.
These future studies will direct the development of new
therapeutic options for millions of individuals with pain-
ful rheumatic disorders.
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